PEN vs. WST, BAX, PODD, SWAV, TFX, SOLV, GMED, GKOS, MMSI, and HAE
Should you be buying Penumbra stock or one of its competitors? The main competitors of Penumbra include West Pharmaceutical Services (WST), Baxter International (BAX), Insulet (PODD), Shockwave Medical (SWAV), Teleflex (TFX), Solventum (SOLV), Globus Medical (GMED), Glaukos (GKOS), Merit Medical Systems (MMSI), and Haemonetics (HAE). These companies are all part of the "surgical & medical instruments" industry.
Penumbra (NYSE:PEN) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.
Penumbra received 531 more outperform votes than West Pharmaceutical Services when rated by MarketBeat users. Likewise, 80.43% of users gave Penumbra an outperform vote while only 55.74% of users gave West Pharmaceutical Services an outperform vote.
West Pharmaceutical Services has higher revenue and earnings than Penumbra. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.
Penumbra currently has a consensus price target of $300.64, indicating a potential upside of 59.11%. West Pharmaceutical Services has a consensus price target of $435.20, indicating a potential upside of 38.30%. Given Penumbra's higher probable upside, equities analysts plainly believe Penumbra is more favorable than West Pharmaceutical Services.
West Pharmaceutical Services has a net margin of 19.42% compared to Penumbra's net margin of 8.52%. West Pharmaceutical Services' return on equity of 20.57% beat Penumbra's return on equity.
In the previous week, Penumbra had 5 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 11 mentions for Penumbra and 6 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 1.69 beat Penumbra's score of 0.74 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.
88.9% of Penumbra shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 5.0% of Penumbra shares are owned by insiders. Comparatively, 0.5% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Penumbra has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.
Summary
West Pharmaceutical Services beats Penumbra on 11 of the 18 factors compared between the two stocks.
Get Penumbra News Delivered to You Automatically
Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Penumbra Competitors List
Related Companies and Tools
